SCHEMBL2473155

SCHEMBL2473155

Cc1[nH]c2c(NCc3ccccc3)nccc2c1C

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 4/20 0.70
CYP3A4 P08684 4/20 0.70
CYP2C19 P33261 3/20 0.70
CYP2C9 P11712 2/20 0.70
EGFR P00533 3/20 0.54
UTS2R Q9UKP6 1/20 0.51
MEN1 O00255 3/20 0.47
KMT2A Q03164 3/20 0.47
CYP2D6 P10635 4/20 0.46
ALDH1A1 P00352 2/20 0.46
KDM4E B2RXH2 1/20 0.46
HPGD P15428 1/20 0.46
NOS2 P35228 1/20 0.44
ADORA2A P29274 1/20 0.44
ADORA1 P30542 1/20 0.44
TSHR P16473 2/20 0.44
LMNA P02545 1/20 0.44
CDK2 P24941 1/20 0.44
MAPK1 P28482 1/20 0.44
CSF1R P07333 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL1738610 0.99 CYP1A2 (0.68) CYP1A2CYP3A4CYP2C19CYP2C9EGFR
SCHEMBL2475800 0.85 CYP1A2 (0.55) CYP1A2CYP3A4CYP2C19CYP2C9EGFR
SCHEMBL2475414 0.84 CYP1A2 (0.54) CYP1A2CYP3A4CYP2C19CYP2C9EGFR
SCHEMBL2474287 0.84 CYP3A4 (0.74) CYP1A2CYP3A4CYP2C19CYP2C9EGFR
SCHEMBL2470230 0.83 CYP1A2 (0.50) CYP1A2CYP3A4CYP2C19CYP2C9EGFR
SCHEMBL2475860 0.82 CYP1A2 (0.49) CYP1A2CYP3A4CYP2C19CYP2C9EGFR
SCHEMBL2473550 0.82 CYP3A4 (1.00) CYP1A2CYP3A4CYP2C19CYP2C9EGFR
SCHEMBL2473147 0.79 CYP3A4 (0.60) CYP1A2CYP3A4CYP2C19CYP2C9EGFR
SCHEMBL2474375 0.77 CYP3A4 (0.55) CYP1A2CYP3A4CYP2C19CYP2C9EGFR
SCHEMBL2475050 0.77 EGFR (0.60) CYP1A2CYP3A4CYP2C19CYP2C9EGFR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1787991-B2 PYRROLO[2,3-c]PYRIDINE COMPOUND, PROCESS FOR PRODUCING THE SAME, AND USE TAKEDA PHARMACEUTICALS CO (JP) 2020-06-24 EP disclosed
US-20180148446-A1 PYRROLO [2,3-c] PYRIDINE COMPOUND, PROCESS FOR PRODUCING THE SAME, AND USE TAKEDA PHARMACEUTICALS CO (JP) 2018-05-31 US disclosed
EP-1787991-B1 PYRROLO[2,3-c]PYRIDINE COMPOUND, PROCESS FOR PRODUCING THE SAME, AND USE TAKEDA PHARMACEUTICAL (JP) 2011-10-05 EP disclosed
EP-1784404-A4 PYRROLO[2,3-C]PYRIDINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF YUHAN CORP (KR) 2009-09-09 EP disclosed
US-20070293532-A1 Pyrrolo [2,3-C] Pyridine Compound, Process for Producing the Same, and Use TAKEDA PHARMACEUTICAL COMPAN6Y LIMITED (JP) 2007-12-20 US disclosed
EP-1787991-A1 PYRROLOÝ2,3-c¨PYRIDINE COMPOUND, PROCESS FOR PRODUCING THE SAME, AND USE Takeda Pharmaceutical Company Limited (JP) 2007-05-23 EP disclosed
EP-1784404-A1 PYRROLO[2,3-C]PYRIDINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF Yuhan Corporation (KR) 2007-05-16 EP disclosed
WO-2006025716-A1 PYRROLO[2,3-C]PYRIDINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF YUHAN CORPORATION (KR) 2006-03-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180148446-A1 PYRROLO [2,3-c] PYRIDINE COMPOUND, PROCESS FOR PRODUCING THE SAME, AND USE PGA5, ATP6AP1, PPA1 CYP1A2 196/4885CYP3A4 114/4885CYP2C19 99/4885
US-20070293532-A1 Pyrrolo [2,3-C] Pyridine Compound, Process for Producing the Same, and Use PGA5, ATP6AP1, PPA1 CYP1A2 196/4885CYP3A4 114/4885CYP2C19 99/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.